<DOC>
	<DOCNO>NCT02986932</DOCNO>
	<brief_summary>This prospective , non-randomized , single-arm , feasibility study evaluate safety initial effectiveness open Blood-Brain Barrier intravenous contrast agent use ExAblate Neuro System patient early stage Alzheimer 's Disease .</brief_summary>
	<brief_title>Blood-Brain-Barrier Opening Using Focused Ultrasound With IV Contrast Agents Patients With Early Alzheimer 's Disease</brief_title>
	<detailed_description>This study prospective , single-arm , non-randomized , feasibility , phase I trial evaluate safety focal BBB opening use ExAblate® Transcranial ( 220 kHz ) system Definity® ultrasound contrast 6 patient mild Alzheimer 's Disease . This phase I trial divide two stage . In first stage , patient undergo small volume BBB opening , establish minimum require sonication parameter open BBB , evidence gadolinium enhancement T1-weighted MRI . Stage I define discrete region approximately 9 mm x 9 mm area right frontal lobe . Multiple sonications perform start low energy ramp BBB observe open . The subject remove ExAblate® Neuro device follow safety 30 day . If subject experience BBB open without serious adverse effect ( brain edema ) , subject may proceed Stage two large volume ( 2.5-3.0 cm ) target . Subjects follow additional 60 day safety preliminary effectiveness .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Probable AD consistent NIA/AA criterion ( McKhann , Alzheimer &amp; Dementia 2011 ) 2 . Modified Hachinski Ischemia Scale ( MHIS ) score &lt; = 4 . 3 . Mini Mental State Exam ( MMSE ) score 1828 4 . Short form Geriatric Depression Scale ( GDS ) score &lt; = 6 5 . Has Florbetaben PET scan consistent presence amyloid pathology propose target region ( right frontal lobe ) 6 . Able communicate sensation ExAblate® MRgFUS procedure . 1 . MRI finding : Active infection/inflammation Acute chronic hemorrhage , specifically &gt; 4 lobar microbleeds , siderosis macrohemorrhages Tumor/space occupy lesion Meningeal enhancement 2 . More 30 % skull area traverse sonication pathway cover scar , scalp disorder ( e.g. , eczema ) , atrophy scalp 3 . Clips metallic implanted object skull brain , except shunt ; metallic object implant body 4 . Significant cardiac disease unstable hemodynamic status include : 5 . Uncontrolled hypertension medication abnormal ECG 6 . Medications know increase risk hemorrhage , ( e.g . : patient aspirin another anticoagulant least 7 day prior treatment ) anticoagulant ( class I III ) Avastin 30 day 7 . History bleed disorder , coagulopathy history spontaneous hemorrhage use anticoagulants 8 . Abnormal coagulation profile ( PLT &lt; 100,00/μl ) , PT ( &gt; 14 sec ) PTT ( &gt; 36 sec ) , INR &gt; 1.3 9 . No 1 nonstrategic lacune &lt; 1.5 cm 10 . Known cerebral systemic vasculopathy 11 . Significant depression potential risk suicide 12 . Known sensitivity/allergy gadolinium ( alternative product may use ) , Definity component . 13 . Any contraindication MRI scan metallic implant , claustrophibia large MRI scanner 14 . Untreated , uncontrolled sleep apnea 15 . Impaired renal function estimate glomerular filtration rate &lt; 30 mL/min/1.73m2 16 . Does reliable caregiver frequent contact patient accompany patient clinic treatment available telephone designate time . Participants live retirement home may include . Caregiver willing sign Informed Consent Form 17 . Respiratory : chronic pulmonary disorder e.g . severe emphysema , pulmonary vasculitis , cause reduced pulmonary vascular crosssectional area , patient history drug allergy , asthma hay fever , multiple allergy benefit/risk administer Definity® consider unfavorable study physician relation product monograph Definity . 18 . Currently clinical teial involve investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Blood-Brain Barrier</keyword>
</DOC>